연구성과로 돌아가기

2025 연구성과별 연구자 정보 (360 / 1187)

※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Document Title Author Full Name Author Short Name Index Corresponding Address ResearcherID ResearcherID Author Name ORCID ORCID Author Name Related Email
Efficacy and safety of elebsiran and pegylated interferon alfa combination therapy versus pegylated interferon alfa in participants with chronic hepatitis B virus infection: follow-up results from the ongoing phase 2, randomized, open-label ENSURE study Zhu, Chong Zhu, C 9 Brii Biosci Beijing Co Ltd, Beijing, Peoples R China jia_jd@ccmu.edu.cn;
Efficacy and safety of elebsiran and pegylated interferon alfa combination therapy versus pegylated interferon alfa in participants with chronic hepatitis B virus infection: follow-up results from the ongoing phase 2, randomized, open-label ENSURE study Wu, Yue Wu, Y 10 Brii Biosci Beijing Co Ltd, Beijing, Peoples R China jia_jd@ccmu.edu.cn;
Efficacy and safety of elebsiran and pegylated interferon alfa combination therapy versus pegylated interferon alfa in participants with chronic hepatitis B virus infection: follow-up results from the ongoing phase 2, randomized, open-label ENSURE study Chen, Xiaofei Chen, XF 11 Brii Biosci Beijing Co Ltd, Beijing, Peoples R China jia_jd@ccmu.edu.cn;
Efficacy and safety of elebsiran and pegylated interferon alfa combination therapy versus pegylated interferon alfa in participants with chronic hepatitis B virus infection: follow-up results from the ongoing phase 2, randomized, open-label ENSURE study Margolis, David Margolis, D 12 Brii Biosci Inc, Durham, USA jia_jd@ccmu.edu.cn;
Efficacy and safety of elebsiran and pegylated interferon alfa combination therapy versus pegylated interferon alfa in participants with chronic hepatitis B virus infection: follow-up results from the ongoing phase 2, randomized, open-label ENSURE study Zhu, Qing Zhu, Q 13 Brii Biosci Inc, Durham, USA jia_jd@ccmu.edu.cn;
Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study Jun, Jae-Bum Jun, JB 1 Hanyang Univ, Hosp Rheumat Dis, Dept Rheumatol, Seoul, South Korea drsong@cau.ac.kr;
Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study Lee, Hye-Soon Lee, HS 2 Hanyang Univ, Guri Hosp, Dept Internal Med, Div Rheumatol,Coll Med, Guri, South Korea drsong@cau.ac.kr;
Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study Kim, Sang-Hyon Kim, SH 3 Keimyung Univ, Coll Med, Dept Internal Med, Div Rheumatol, Daegu, South Korea drsong@cau.ac.kr;
Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study Lee, Seung-Geun Lee, SG 4 Pusan Natl Univ, Sch Med, Dept Internal Med, Div Rheumatol, Busan, South Korea drsong@cau.ac.kr;
Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study Lim, Doo-Ho Lim, DH 5 Univ Ulsan, Coll Med, Ulsan Univ Hosp, Div Rheumatol,Dept Internal Med, Ulsan, South Korea drsong@cau.ac.kr;
Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study Kim, Jinhyun Kim, J 6 Chungnam Natl Univ, Coll Med, Dept Internal Med, Div Rheumatol, Daejeon, South Korea drsong@cau.ac.kr;
Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study Park, Yong-Beom Park, YB 7 Yonsei Univ, Coll Med, Dept Internal Med, Div Rheumatol, Seoul, South Korea IVH-2192-2023 Park, Yong-Beom drsong@cau.ac.kr;
Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study Lim, Mie Jin Lim, MJ 8 Inha Univ, Dept Internal Med, Div Rheumatol, Incheon, South Korea drsong@cau.ac.kr;
Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study Hong, Seung-Jae Hong, SJ 9 Kyung Hee Univ, Kyung Hee Univ Hosp, Coll Med, Dept Rheumatol, Seoul, South Korea drsong@cau.ac.kr;
Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study Choi, Hyo-Jin Choi, HJ 10 Gachon Univ, Gil Med Ctr, Dept Internal Med, Div Rheumatol, Incheon, South Korea drsong@cau.ac.kr;
페이지 이동: